The cognition game study

Not Applicable

Completed

• Conditions: Cognitive impairment in psychiatric patients (we included subjects with schizophrenia/schizo-affective disorder, major depressive disorder and obsessive compulsive disorder; Mental and Behavioural Disorders

• Registration Number: ISRCTN60175188
• Lead Sponsor: MyCognition

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2017-06-13
• Study Start: 2017-09-11
• Last Update Posted: 6 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Ability to give informed consent
2. Where participants are of legal childhood age, consent will also be obtained from one of the participant’s parents. Both the parent and participant will be required to sign the consent form in such a case. It will be the investigator’s responsibility to determine whether a participant of legal childhood age has the capacity to consent to the study.
3. Age 16 - 55 years old
4. DSM-IV-TR diagnosis of schizophrenia/schizoaffective disorder, obsessive compulsive disorder or major depressive disorder
5. Fluent in Dutch
6. Clinically stable

Exclusion Criteria

1. High risk of suicide (score of 2 or more on HAM-D suicide item)
2. Unstable medical disorder
3. Having met the criteria for a substance abuse disorder in the last three months (measured by the MINI-plus)
4. History of a clinically significant abnormality of the neurological system (including dementia and other cognitive disorders or significant head injury) or any history of seizure (excluding febrile seizure)
5. Premorbid IQ < 70

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive functioning is measured using CANTAB and MyCQ at baseline and 12 weeks after the intervention.

Secondary Outcome Measures

Name	Time	Method
<br> 1. Cognitive functioning is asssessed using the MyCQ at week 4 and week 8<br> 2. Severity of symptoms is measured using PANSS for psychotic patients, YBOCS for OCD patients and IDS for depressed patients at baseline and 12 weeks<br> 3. Blood marker abnormalities is measured using blood collection at baseline<br> 4. Electro-encephalogram (EEG) is measured using the P300 and Mismatch negativity and resting state at baseline and 12 weeks<br> 5. Level of functioning is measured using GAF Score at baseline and 12 weeks<br> 6. Cortisol level is measured using hair analysis at baseline and 12 weeks<br>